Skip to content
Subscriber Only

Servier Said to Face EU Drug-Delay Fine With Teva Next Month

Les Laboratoires Servier and Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, face European Union antitrust fines as soon as next month over agreements that delayed the release of cheaper versions of a Servier hypertension treatment.

As many as four other companies may also be penalized by the European Commission for hampering the generic entry of perindopril, a cardiovascular drug, said three people familiar with the case, who asked not to be identified because the decision isn’t public. The fines are expected by the end of July when the EU regulator begins a vacation period, they said.